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Chronic kidney disease (CKD) is a public health problem, and an unfavorable lifestyle has
been suggested as a modifiable risk factor for CKD. Cigarette smoking is closely associated
with cardiovascular disease and cancers; however, there is a lack of evidence to prove that
smoking is harmful for kidney health. Therefore, we aimed to determine the relationship
between cigarette smoking and CKD among healthy middle-aged adults.
Methods
Using the database from the Korean Genome and Epidemiology Study, we analyzed 8,661
participants after excluding those with baseline estimated glomerular filtration rate (eGFR)
<60 ml/min/1.72 m2 or proteinuria. Exposure of interest was smoking status: never-, former-
, and current-smokers. Primary outcome was incident CKD defined as eGFR <60 ml/min/
1.73 m2 or newly developed proteinuria.
Results
The mean age of the subjects was 52 years, and 47.6% of them were males. There were
551 (6.4%) and 1,255 (14.5%) subjects with diabetes and hypertension, respectively. The
mean eGFR was 93.0 ml/min/1.73 m2. Among the participants, 5,140 (59.3%), 1,336
(15.4%), and 2,185 (25.2%) were never-smokers, former-smokers, and current-smokers,
respectively. During a median follow-up of 11.6 years, incident CKD developed in 1,941
(22.4%) subjects with a crude incidence rate of 25.1 (24.0–26.2) per 1,000 person-years.
The multivariable Cox regression analysis after adjustment of confounding factors showed
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hazard ratios (95% confidence interval) of 1.13 (0.95–1.35) and 1.26 (1.07–1.48) for CKD
development in the former- and current-smokers, compared with never-smokers.
Conclusion
This study showed that smoking was associated with a higher risk of incident CKD among
healthy middle-aged adults.
Introduction
Chronic kidney disease (CKD) is a growing public health problem. According to the Global
Burden of Disease Study 2016, more than 200 million people worldwide have CKD [1]. In
addition, in the United States, the number of patients with end-stage renal disease (ESRD)
who require renal replacement therapy (RRT) is more than 400,000 [2]. Many studies identi-
fied risk factors, such as advanced age, hypertension, diabetes mellitus (DM), dyslipidemia,
obesity, and usage of nephrotoxic agents, for CKD [3–9], Because CKD is accompanied by
concomitant disease burden, increased mortality, and high healthcare cost, management of
the modifiable risk factors should be the key strategy for prevention of CKD.
Cigarette smoking is a leading cause for preventable death from cardiovascular disease
(CVD) and cancer [10]. Although controversial, several studies have shown that the risk of
incident CVD decreases with increase in the smoking cessation period [11–14]. In addition,
smoking cessation at an earlier age is associated with lower risk of death [15, 16]. Therefore,
cigarette smoking is considered an important modifiable risk factor, and smoking cessation
has become a major target policy for many countries. Smoking promotes atherosclerosis and
vascular dysfunction; hence, it can cause damage to other organs, including the kidney. In fact,
many epidemiologic studies to date have demonstrated the negative impacts of smoking on
kidney health [17–25]. Although there have been several observational studies that determined
the effects of smoking exposure on kidney function, assessments comparing the risk of kidney
damage with those who stopped smoking after active smoking periods have been limited. In
addition, the duration of most previous reports was relatively short and could not evaluate the
long-term effects of smoking on kidney function. [20, 26–28].
In this study, we sought to clarify the long-term relationship between smoking and kidney
function in healthy middle-aged Korean adults. In addition, we examined whether smoking
cessation can help prevent kidney disease.
Materials and methods
Study design and subjects
The Korean Genome and Epidemiology Study (KoGES) is a population-based cohort study
conducted in rural (Ansung) and urban (Ansan) areas of South Korea. This study was
designed to elucidate the interaction between lifestyle factors and genetic risk factors in the
development of non-communicable diseases, including CKD. The detailed profile and meth-
ods on construction of the KoGES cohort are described elsewhere [29]. Briefly, 10,030 partici-
pants were enrolled between 2001 and 2002. Biannual health examinations and surveys were
provided to the participants until 2014, and the retention rate was 62.8% at the end of the 6th
follow-up phase. We excluded (a) patients with estimated glomerular filtrating rate (eGFR)
<60 mL/min/1.73 m2, (b) those with urine dipstick positive proteinuria� 1+ at baseline, (c)
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those with missing follow-up data for serum creatinine level or urinary dipstick test, and (d)
those without available information for smoking status (Fig 1). Thus, 8,661 participants were
included in the final analysis. All participants provided informed consent. The present study
was carried out in accordance with the Declaration of Helsinki and was approved by the Insti-
tutional Review Board of Yonsei University Health System Clinical Trial Center (4-2016-
0100).
Data measurement
Demographic and socioeconomic data, including age, sex, medical history, education and
income levels, smoking status, and alcohol intake were obtained using a standardized self-
administered questionnaire at enrollment. Patients with a history of alcohol intake were cate-
gorized as non- or current drinkers. Blood pressure was measured by trained nurses using a
standard mercury sphygmomanometer with the subject in the sitting position after a 5-min
rest. Blood and urine samples were obtained after an 8-h fast and transported to a central labo-
ratory (Seoul Clinical Laboratories, Seoul, Republic of Korea) within 24 hours of sampling.
Serum concentrations of blood urea nitrogen, creatinine, albumin, glucose, total cholesterol,
triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C),
and C-reactive protein (CRP) were measured. Urine samples were collected in the morning
after the first voiding and were subjected to a dipstick test (URISCAN Pro II; YD Diagnostics
Corp., Seoul, Korea). The presence of proteinuria was defined as protein level 1+ in the dip-
stick urine test. The eGFR was calculated using the CKD epidemiology collaboration equation.
Exposure and study outcome
The primary exposure of interest was smoking status, and the subjects were classified as non-,
former-, and current-smokers. Data for age at initiation of smoking, number of years smoked,
Fig 1. Flow diagram of the study cohort. Abbreviation: eGFR, estimated glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0238111.g001
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and average number of packs of cigarettes smoked per day were also collected from the for-
mer- and current-smokers. The smoking pack-years were calculated as the number of years
smoked × the average number of packs of cigarettes smoked per day. The surveys collected at
enrollment and the second visit were used to assess baseline smoking status.
The primary outcome was incident CKD, which was defined as the occurrence of eGFR
<60 ml/min/1.73 m2 or newly developed proteinuria (defined as urine dipstick protein�1+).
The study observation ended on December 31, 2014.
Statistical analysis
All statistical analyses were performed using STATA version 15.1 (StataCorp, College Station,
TX, USA). For missing data imputation, the MICE (multivariate imputation by chained equa-
tions) method of multiple multivariate imputation in STATA was used. The missing data anal-
ysis procedures used missing at random assumptions (S1 Table). We independently analyzed 5
copies of the data, each with missing values suitably imputed, in the multivariable cox regres-
sion analyses. The estimates of the variables were averaged to give a single mean estimate and
standard errors were adjusted according to Rubin’s rules [30]. The continuous variables were
expressed as mean ± standard deviation or median and interquartile ranges, while the categori-
cal variables were expressed as frequencies with percentages. All data were tested for normality
before statistical analysis. The Kolmogorov-Smirnov test was performed to determine the nor-
mality of distribution of the parameters. Comparisons between groups were performed using
analysis of variance with a normal distribution, and the chi-square test or Fisher’s exact test
was used for analysis of the categorical variables. Data that did not show a normal distribution
were compared using the Kruskal-Wallis test. Cumulative renal survival rates were estimated
by Kaplan-Meier analysis and a log-rank test. Multivariable Cox proportional hazard models
with a 3-step adjustment level were constructed to determine the independent association of
smoking status with incident CKD. The proportionality assumptions for the cause-specific
models were tested through inspection of log (-log [survival]) curves, and no violations were
observed. Multivariable models were constructed with adjustment for confounding factors.
Variables that showed statistical significance in univariable regression analyses were selected
for the multivariable model. Model 1 was adjusted for age and sex. Model 2 was further
adjusted for comorbidities and socioeconomic factors such as, hypertension, DM, alcohol sta-
tus, education, income level, and BMI. Model 3 was fully adjusted for the above factors plus
laboratory results including albumin and total cholesterol level. The results of the Cox models
were presented as HR and 95% confidence interval (CI). Patients who were lost to follow-up
or death were censored at the date of the last examination. To test the dose-response relation-
ship between smoking load and incident CKD, we repeated the same Cox analysis after the
smokers were classified by 15-year increment in pack-years of smoking. We also performed
the subgroup analyses across the following subgroups: age (<60 and�60 years), sex, hyperten-
sion, DM, body mass index (BMI) (<25 and�25 kg/m2), alcohol status, and income and edu-
cation levels. In addition, the association between smoking cessation and risk of the adverse
kidney outcome among former-smokers classified by 10-year increments of cessation duration
was assessed. For subgroup analysis, the interaction terms between each stratifying factor and
smoking status on incident CKD was assessed in adjusted cause-specific proportional hazard
models using the likelihood ratio test. Adjustments were made with the fully adjusted model 3
of the multivariable Cox proportional hazard models. Linear mixed-effect models of annual
eGFR decline according to smoking status and timed updated smoking status were con-
structed with adjustment of confounding factors. For all analyses, p<0.05 was considered sta-
tistically significant.
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Results
Baseline characteristics
The baseline characteristics by smoking status are shown in Table 1. The mean age of the
study cohort was 52 years and 47.6% were men. There were 551 (6.4%) subjects with diabetes
and 1,255 (14.5%) with hypertension. The mean eGFR was 93.0 ml/min/1.73 m2. Among
the participants, 5,140 (59.3%), 1,336 (15.4%), and 2,185 (25.2%) were never-smokers,
Table 1. Baseline characteristics of participants according to smoking status.
Variables Total Never smokers Smokers
Ever smokers Former smokers Current smokers
(n = 8,661) (n = 5,140) (n = 3,521) (n = 1,336) (n = 2,185)
Smoking
Smoking period (years) 10.0±14.1 24.5±11.4 20.1±11.4 27.2±10.5
Smoking load (pack-year) 9.5±15.9 23.3±17.2 21.0±18.6 24.8±16.2
Age (years) 52.1±8.8 52.3±8.8 51.7±8.8 52.4±9.0 51.3±8.7
Male, n (%) 4,124 (47.6) 818 (15.9) 3,306 (93.9) 1,283 (96.0) 2,023 (92.6)
Body mass index (kg/m2) 24.6±3.2 24.8±3.2 24.2±3.0 24.5±2.8 23.9±3.1
Systolic BP (mmHg) 121.3±18.2 121.3±19.0 121.2±17.1 123.1±17.3 120.1±16.8
Diastolic BP (mmHg) 80.2±11.4 79.5±11.6 81.3±10.9 82.5±11.0 80.5±10.7
Comorbidities, n (%)
Hypertension 1,255 (14.5) 810 (15.8) 445 (12.6) 217 (16.2) 228 (10.4)
Diabetes 551 (6.4) 294 (5.7) 257 (7.3) 111 (8.3) 146 (6.7)
Cardiovascular disease 63 (0.7) 39 (0.8) 24 (0.7) 15 (1.1) 9 (0.4)
Alcohol, n (%) 4,096 (47.3) 1,548 (30.1) 2,548 (72.4) 903 (67.6) 1,645 (75.3)
Educationb, n (%)
Low 2,857 (33.0) 2,087 (40.6) 770 (21.9) 264 (19.8) 506 (23.2)
Middle 4,590 (53.0) 2,567 (49.9) 2,023 (57.5) 760 (56.9) 1,263 (57.8)
High 1,214 (14.0) 486 (9.5) 774 (20.7) 312 (23.4) 416 (19.0)
Incomec, n (%)
Low 2,991 (34.5) 1,967 (38.3) 1,024 (29.1) 342 (25.6) 682 (31.2)
Middle 4,036 (46.6) 2,313 (45.0) 1,723 (48.9) 666 (49.9) 1,057 (48.4)
High 1,634 (18.9) 860 (16.7) 774 (22.0) 328 (24.6) 446 (20.4)
Laboratory findings
WBC count (103/μL) 6.5±1.8 6.3±1.7 6.9±1.9 6.4±1.6 7.2±1.9
Hemoglobin (g/dL) 13.6±1.6 12.9±1.4 14.6±1.2 14.6±1.2 14.7±1.2
Albumin (g/dL) 4.2±0.3 4.2±0.3 4.3±0.4 4.4±0.4 4.3±0.3
eGFR (mL/min/1.73m2) 93.0±13.0 93.7±12.8 91.9±13.3 90.2±13.4 92.9±13.1
Total cholesterol (mg/dL) 190.6±35.0 190.0±34.4 191.3±35.9 194.0±35.5 189.7±36.1
LDL-cholesterol (mg/dL) 113.7±33.1 114.8±31.5 112.2±35.2 115.5±34.6 110.1±35.4
HDL-cholesterol (mg/dL) 44.7±10.0 45.3±9.9 43.7±10.0 43.9±9.6 43.6±10.2
Triglyceridea (mg/dL) 135 [99, 189] 127 [95, 176] 148 [110, 210] 146 [108, 200] 149 [110, 217]
CRPa (mg/dL) 0.14 [0.07, 0.25] 0.14 [0.07, 0.24] 0.15 [0.07, 0.26] 0.14 [0.07, 0.26] 0.15 [0.07, 0.26]
All data are expressed as mean ± SD or a median (and interquartile range).
b Low, primary education; middle, secondary education; and high, tertiary education.
c Low, <1,000,000;�1,000,000 and <3,000,000; and high,�3,000,000 won per month.
Abbreviations: BP, blood pressure; WBC, white blood cell; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein, and
CRP, high-sensitivity C-reactive protein.
https://doi.org/10.1371/journal.pone.0238111.t001
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former-smokers, and current-smokers, respectively. There were more patients with diabetes
but fewer patients with hypertension among smokers than among never smokers. Smokers
consumed more alcohol and had higher levels of education and income than non-smokers.
Baseline kidney function was slightly better in non-smokers than in smokers.
Risk of the incident CKD according smoking status
During a median follow-up of 11.6 years, incident CKD developed in 1,941 (22.4%) subjects
with a crude incidence rate of 25.1 (24.0–26.2) per 1,000 person-years. Poisson regression after
adjustment of confounding factors showed that the incidence rate ratio (IRR) of incident CKD
was highest in the current smoking group (Fig 2). IRRs (95% confidence interval) were 1.11
(0.94–1.33) and 1.19 (1.01–1.39) in the former smokers and current smokers, compared with
Fig 2. Adjusted incidence rate ratio of CKD according to smoking status. Abbreviation: IRR, incidence rate ratio.
https://doi.org/10.1371/journal.pone.0238111.g002
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never smokers. The Kaplan-Meier plots showed that the time to the development of incident
CKD was significantly longer in never smokers than current smokers or former smokers (Fig
3). The multivariable Cox regression analysis after adjustment of confounding factors showed
hazard ratios (95% CI) of 1.13 (0.95–1.35) and 1.26 (1.07–1.48) for CKD development in the
former- and current-smokers, compared with never-smokers (Table 2). Additionally, linear
Fig 3. Kaplan-Meier curve for incident CKD.
https://doi.org/10.1371/journal.pone.0238111.g003
Table 2. Hazard ratios for incident CKD by smoking status.
Model 1 Model 2 Model 3
HRs (95% CI) p HRs (95% CI) p HRs (95% CI) p
Never smokers Reference Reference Reference
Former smokers 1.14 (0.95–1.35) 0.140 1.13 (0.95–1.35) 0.174 1.13 (0.95–1.35) 0.164
Current smokers 1.15 (0.99–1.35) 0.075 1.25 (1.07–1.47) 0.006 1.26 (1.07–1.48) 0.005
Model 1: Adjusted for age and sex.
Model 2: Model 1 + HTN, DM, alcohol, education, income, and BMI.
Model 3: Model 2 + Albumin and total cholesterol.
Abbreviations: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0238111.t002
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mixed-effects models were constructed, using repeated eGFR measurements of each partici-
pant, to evaluate the effect of smoking status on the decline slope of eGFR. The annual eGFR
decline was more rapid among current smokers (-1.569 mL/min/1.73m2/year) compared to
never smokers (-1.282 mL/min/1.73m2/year, p<0.001) or former smokers (-1.274 mL/min/
1.73m2/year, p<0.001) (S2 Table). A similar relationship between smoking status and annual
eGFR decline was also found when smoking status was treated as a time dependent variable
(S3 Table).
Dose-dependent relationship between smoking load and incident CKD
Next, we analyzed the association between smoking load and incident CKD. Smokers were
classified into 3 groups by pack-years of smoking (15-year increments). The HRs (95% CIs)
were 1.14 (0.94–1.37), 1.07 (0.85–1.34), and 1.12 (0.93–1.36) for- <15, 15–29, and�30 pack-
years of smoking, respectively, as compared to never-smokers (Table 3). However, the differ-
ences were not statistically significant.
Subgroup analysis
Further examinations were done to evaluate the association between smoking and kidney out-
come in subgroups stratified by sex, age (<60 or�60 years), presence of hypertension and dia-
betes, BMI (<25 or�25 kg/m2), alcohol status, and income and educational levels. When the
interaction terms between each stratifying factor and the effect of current-smoking on incident
CKD was assessed, no significant interactions were found in any of the subgroups. This sug-
gests that the increased incident CKD risk in current smokers compared to never smokers
were consistently significant across these subgroups (S4 Table).
Smoking cessation and risk of incident CKD
Finally, to assess whether smoking cessation can aid in preventing CKD development, we sub-
divided the former smokers into three groups by cessation duration in 10-year increments.
After adjusting for the confounding factors, smoking cessation for 20 years and more showed
relationship with lower risk of incident CKD (HR, 0.76; 95% CI, 0.62–0.94), while quitting
smoking for less than 20 years was not (Table 4).
Table 3. Hazard ratios for incident CKD according to smoking load.
Model 1 Model 2 Model 3
HRs (95% CI) p HRs (95% CI) p HRs (95% CI) p
Never smokers Reference Reference Reference
Smoking load
0–15 pack x year 1.11 (0.94–1.32) 0.222 1.16 (0.97–1.38) 0.101 1.14 (0.94–1.37) 0.187
15–30 pack x year 1.04 (0.85–1.28) 0.683 1.12 (0.91–1.38) 0.277 1.07 (0.85–1.34) 0.567
>30 pack x year 1.14 (0.95–1.36) 0.150 1.19 (1.00–1.42) 0.054 1.12 (0.93–1.36) 0.229
Model 1: Adjusted for age and sex.
Model 2: Model 1 + HTN, DM, alcohol, education, income, and BMI.
Model 3: Model 2 + Albumin and total cholesterol.
Abbreviations: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0238111.t003
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Discussion
In this population-based cohort study with a median follow-up of 11.6 years, we found that
current smoking was associated with a higher risk of CKD development in middle-aged people
without kidney disease. In addition, among former smokers, smoking cessation for� 20 years
was associated with a lower risk of incident CKD, suggesting that quitting smoking may be
helpful in preventing the development of CKD.
Our findings add evidence to the prevailing notion that smoking is harmful for vascular
health. Regarding kidney disease, previous studies have shown that smoking is associated with
the presence of proteinuria and impaired kidney function [21–23, 26, 27, 31, 32]. However,
our study was different in several aspects. Many previous studies were cross-sectional or retro-
spective observations [21, 23, 31, 32], did not have follow-up measures for kidney function
[22], and defined the study outcome as ESRD [26, 27]. The strengths of the present study lie in
the analyses with well-organized longitudinal data from a prospective cohort, long-term obser-
vation, and rigorous adjustment of many confounding factors. Because people in our cohort
had normal kidney function and few comorbid conditions at study entry, more severe kidney
outcomes such as ESRD rarely occurred during follow-up. However, our longitudinal long-
term observation over a 11-year duration enabled us to detect early CKD development in
healthy middle-aged people without kidney disease. Thus, our findings, along with those of
previous studies, confirm the harmful impact of smoking on kidney health in people who do
not have overt kidney disease.
To date, few studies have addressed whether smoking is a modifiable factor for the preven-
tion of kidney disease. However, this can be inferred from previous studies in the field of car-
diovascular disease research. In a collective analysis using the Cochrane database, quitting
smoking was associated with 36% and 32% lower risk of mortality and non-fatal myocardial
infarctions, respectively, among patients with coronary heart disease [33]. Accordingly, all
guidelines recommend quitting smoking as a first-line measure for the prevention of cardio-
vascular disease based on many epidemiologic studies [11, 34–36]. The effect of smoking cessa-
tion on kidney failure has recently been studied in two large cohorts [26, 37]. Both studies
conducted using the Singapore Chinese and Norwegian cohorts showed that the risk of kidney
failure, defined as progression to CKD stage 5 or the initiation of dialysis treatment, was lower
in people with prolonged smoking cessation. In agreement with these studies, we showed that
early smoking cessation was associated with a lower risk of CKD development among former
smokers. However, the time elapsed to observe the beneficial effects of smoking cessation
appears to be longer because the statistical significance was observed in those who had quit
Table 4. Hazard ratios for incident CKD according to duration of smoking cessation.
Model 1 Model 2 Model 3
HRs (95% CI) p HRs (95% CI) p HRs (95% CI) p
Current smokers Reference Reference Reference
Cessation duration
0–10 years 0.81 (0.61–1.07) 0.145 0.77 (0.58–1.01) 0.063 0.83 (0.63–1.09) 0.181
10–20 years 0.88 (0.68–1.16) 0.369 0.84 (0.64–1.10) 0.194 0.89 (0.68–1.17) 0.414
>20 years 0.78 (0.63–0.96) 0.021 0.77 (0.62–0.95) 0.014 0.76 (0.62–0.94) 0.012
Model 1: Adjusted for age and sex.
Model 2: Model 1 + HTN, DM, alcohol, education, income, and BMI.
Model 3: Model 2 + Albumin and total cholesterol.
Abbreviations: HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration; HTN, hypertension; DM, diabetes mellitus; BMI, body mass index.
https://doi.org/10.1371/journal.pone.0238111.t004
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smoking for� 20 years. Presumably, the adverse effects of smoking on the kidney should be
taken into account in light of other cardiovascular system disorders, and its cumulative resid-
ual effects may last longer than expected even after quitting smoking. Taken together, our find-
ings are informative for establishing a preventive strategy against the development of kidney
disease from the viewpoint of public health.
Our study has several limitations. First, this observational study cannot entirely eliminate
confounding, although we rigorously adjusted potential factors that might affect clinical out-
comes. In addition, causality between smoking exposure and incident CKD is uncertain. How-
ever, conducting randomized controlled trials on this issue appear to be infeasible for ethical
reasons. Therefore, collecting more evidence regarding the harmful effects of smoking on kid-
ney disease with well-constructed epidemiologic data would be meaningful. Second, informa-
tion on smoking status relied on a self-reported questionnaire, which might result in
inaccurate classification of smokers. Third, in contrast to other western countries [38, 39],
only 6.1% of the smokers were women, which is consistent with the Korean national health
and nutrition examination survey [40]. The unequal distribution of smokers between men and
women may be similar in other Asian countries as reported in different cohort studies [26, 32].
This smaller proportion of women smokers did not allow us to analyze whether smoking
effects differ between men and women. Fourth, in this study, the magnitude of HR for CKD
development was relatively lower than that in another European cohort study [27], but similar
to that in a Singapore-Chinese cohort study [26]. It is unknown whether there is an ethnic dif-
ference in kidney injury due to smoking exposure. It should be noted that our cohort com-
prised healthy adults with few comorbidities. Thus, a 31% higher risk for CKD development in
this group may be substantial. In addition, the confidence interval was relatively narrow, sug-
gesting the higher accuracy of this analysis. Finally, the inclusion of only Korean people may
limit the generalizability of our findings.
In conclusion, this study showed that cigarette smoking was associated with a higher risk of
CKD development in middle-aged healthy adults without kidney disease. Conversely, smoking
cessation might be associated with a lower risk of incident CKD among former-smokers.
These findings provide robust evidence regarding the harmful effects of smoking on kidney
health and highlight the importance of smoking cessation in preventing kidney disease in clin-
ical practice.
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